Dr. Kyle Wayne Herbold, MD

Dr. Herbold practices at Golden State Dermatopathology in Walnut Creek, California.

Dr. Herbold's NPI, 1568407013, was assigned on June 18, 2006. Dr. Herbold graduated from Yale School of Medicine in 1995. Dr. Herbold holds California license A068815.

Dr. Herbold's primary practice is Golden State Dermatopathology, at 370 N Wiget Ln, Ste 250, Walnut Creek, CA 94598. The practice phone is (925) 278-7592.

Dr. Herbold's primary practice is Golden State Dermatopathology in Walnut Creek, California. The medical group on file is Golden State Dermatology. Dmand AI also links Dr. Herbold to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. Herbold's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Herbold practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Herbold's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Herbold is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Herbold's licenses on file in 2 states: California and Georgia.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, itchy rashes and joint cyst among the conditions Dr. Herbold treats.

CMS data shows 4,777 Medicare services from Dr. Herbold across 18 procedure codes in 2024, for 1,003 Medicare patients. Medicare paid $188,956 for them. Every service was in an office.

CMS counts 1,003 Medicare patients who saw Dr. Herbold in 2024. The largest group is 75 to 84, with 428 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Herbold's median patient age at 68, with 56% women.

In 2024, Dr. Herbold wrote 1,619 Medicare Part D claims for 537 patients. 92% of them were for generic drugs. CMS names the drug for 1,486 of them, across 32 drugs with 11 or more claims each, at $582,961 in total drug cost. In 2023, CMS named 1,133 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Herbold for performance year 2024, reported as part of a group. Dr. Herbold accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 945 procedures of removal of skin lesions by Dr. Herbold, more than 93% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Herbold.

CMS Open Payments shows 146 general payments to Dr. Herbold from 19 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 95% of the total. Eli Lilly and Company paid the most, $447.

Dmand AI lists 2 awards for Dr. Herbold, most recently CMS Stage 1 2012 in 2011.

Dr. Herbold graduated from Yale School of Medicine in 1995. Dr. Herbold is a member of AAD.

Dr. Herbold is in network with 11 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.